

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

None

NNRTI Mutations:

None

RT Other Mutations:

S519N 100%
cons:7,862 • K530KR 0.40%
cons:8,984 G.40%
G.11% • V531W 0.40%
cons:22,862 G.40%
G.11% • A534S 100%
cons:5,642 • A554N 100%
cons:4,394 • V559I 100%
cons:4,884

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations:

None

INSTI Accessory Mutations:

None

IN Other Mutations:

S17N 100%
cons:7,542 • L45IV 1.67%
cons:7,595 G.10%
G.10% • I72V 100%
cons:7,601 • T112I 10%
cons:6,382 • I113V 100%
cons:6,563 • T124A 100%
cons:6,571 • T125TA 0.50%
cons:7,280 G.10%
G.10% • V201I 100%
cons:12,264 • K211T 100%
cons:12,268 • L234I 100%
cons:11,526 • S283G 100%
cons:11,271

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.